Keytruda

News

Keytruda breaks new ground in cervical cancer

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/

News

MSD, Moderna cancer vaccine aces melanoma study

MSD and Moderna’s individualised cancer vaccine mRNA-4157 has shown impressive efficacy in a phase 2b trial in skin cancer melanoma.

News

MSD, Moderna take mRNA jab into phase 3 for lung cancer

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non

News

BMS chases MSD/Seagen with first-line bladder cancer filing

The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting

News

FDA starts review of Padcev/Keytruda for bladder cancer

The FDA has kicked off a priority review of a new combination regimen for previously untreated, locally advanced or metastatic urothelial carcinoma (UC), the most common f

News

Imfinzi faces Keytruda competition in biliary tract cancer

MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch

Keytruda breaks new ground in cervical cancer

MSD, Moderna cancer vaccine aces melanoma study

MSD, Moderna take mRNA jab into phase 3 for lung cancer

BMS chases MSD/Seagen with first-line bladder cancer filing

FDA starts review of Padcev/Keytruda for bladder cancer

Imfinzi faces Keytruda competition in biliary tract cancer

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Keytruda

Editor's Picks